BioPharma Credit PLC
BPCP.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.42 | -0.30 | 0.06 | -3.34 |
| FCF Yield | 10.56% | 10.41% | 14.41% | 7.13% |
| EV / EBITDA | 8.63 | 0.00 | 0.00 | 0.00 |
| Quality | ||||
| ROIC | 10.34% | 8.09% | 13.63% | 6.23% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.92 | 1.14 | 1.01 | 1.14 |
| Growth | ||||
| Revenue 3-Year CAGR | -12.26% | 15.56% | 26.34% | -10.84% |
| Free Cash Flow Growth | -9.15% | -33.15% | 91.09% | 66.06% |
| Safety | ||||
| Net Debt / EBITDA | -0.05 | 0.00 | 0.00 | 0.00 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 93.25 | 54.39 | 39.08 | 39.81 |